<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns="http://purl.org/rss/1.0/"
   xmlns:dc="http://purl.org/dc/elements/1.1/"
   xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
   xmlns:dcterms="http://purl.org/dc/terms/"

>
<channel rdf:about="http://www.citeulike.org/about">
<pubDate>Sat, 26 Jul 2008 05:59:01 BST</pubDate>


	<title>CiteULike: carmenv's curcumin</title>
	<description>CiteULike: carmenv's curcumin</description>


	<link>http://www.citeulike.org/user/carmenv/tag/curcumin</link>
	<dc:publisher>CiteULike.org</dc:publisher>
	<dc:language>en-gb</dc:language>
	<dc:rights>Copyright &#169; 2004-2008 citeulike.org</dc:rights>
	<items>
    <rdf:Seq>
        <rdf:li rdf:resource="http://www.citeulike.org/user/carmenv/article/2734828"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/carmenv/article/2734824"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/carmenv/article/2734788"/>
        <rdf:li rdf:resource="http://www.citeulike.org/user/carmenv/article/2734779"/>

	</rdf:Seq>
	</items>
	</channel>


<item rdf:about="http://www.citeulike.org/user/carmenv/article/2734828">
    <title>Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice.</title>
    <link>http://www.citeulike.org/user/carmenv/article/2734828</link>
    <description>&lt;i&gt;World journal of gastroenterology : WJG, Vol. 14, No. 13. (7 April 2008), pp. 2003-2009.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;AIM: To determine the effect of tetrahydrocurcumin (THC) on tumor angiogenesis compared with curcumin (CUR) by using both in vitro and in vivo models of human hepatocellular carcinoma cell line (HepG2). METHODS: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay was used for testing the anti-proliferating activities of CUR and THC. In male BALB/c nude mice, 2 multiply 10(6) human HepG2 cells were inoculated onto a dorsal skin-fold chamber. One day after HepG2 inoculation, the experimental groups were fed oral daily with CUR or THC (300 mg/kg or 3000 mg/kg). On d 7, 14 and 21, the tumor microvasculature was observed using fluorescence videomicroscopy and capillary vascularity (CV) was measured. RESULTS: Pathological angiogenic features including microvascular dilatation, tortuosity, and hyper-permeability were observed. CUR and THC could attenuate these pathologic features. In HepG2-groups, the CV were significantly increased on d 7 (52.43%), 14 (69.17%), and 21 (74.08%), as compared to controls (33.04%, P &#60; 0.001). Treatment with CUR and THC resulted in significant decrease in the CV (P &#60; 0.005 and P &#60; 0.001, respectively). In particular, the anti-angiogenic effects of CUR and THC were dose-dependent manner. However, the beneficial effect of THC treatment than CUR was observed, in particular, from the 21 d CV (44.96% and 52.86%, P &#60; 0.05). CONCLUSION: THC expressed its anti-angiogenesis without any cytotoxic activities to HepG2 cells even at the highest doses. It is suggested that anti-angiogenic properties of CUR and THC represent a common potential mechanism for their anti-cancer actions.</description>
    <dc:title>Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice.</dc:title>

    <dc:creator>P Yoysungnoen</dc:creator>
    <dc:creator>P Wirachwong</dc:creator>
    <dc:creator>C Changtam</dc:creator>
    <dc:creator>A Suksamrarn</dc:creator>
    <dc:creator>S Patumraj</dc:creator>
    <dc:source>World journal of gastroenterology : WJG, Vol. 14, No. 13. (7 April 2008), pp. 2003-2009.</dc:source>
    <dc:date>2008-04-29T16:19:40-00:00</dc:date>
    <prism:publicationYear>2008</prism:publicationYear>
    <prism:publicationName>World journal of gastroenterology : WJG</prism:publicationName>
    <prism:issn>1007-9327</prism:issn>
    <prism:volume>14</prism:volume>
    <prism:number>13</prism:number>
    <prism:startingPage>2003</prism:startingPage>
    <prism:endingPage>2009</prism:endingPage>
    <prism:category>cancer</prism:category>
    <prism:category>curcumin</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/carmenv/article/2734824">
    <title>Curcumin inhibits WEHI-3 leukemia cells in BALB/c mice in vivo.</title>
    <link>http://www.citeulike.org/user/carmenv/article/2734824</link>
    <description>&lt;i&gt;In vivo (Athens, Greece), Vol. 22, No. 1. (b 2008), pp. 63-68.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;Curcumin (1, 7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5- dione), a natural polyphenol product of the plant Curcuma longa, exhibited potent inhibitory activities against proliferation, induced cell cycle arrest and exhibited the induction of apoptosis in several tumor cell lines. In our previous studies, we have shown that curcumin induced cell cycle arrest and apoptosis on human leukemia HL-60 and mouse leukemia WEHI-3 cells; there are no reports regarding whether or not it affects leukemia cells in vivo. In the present study, we investigated the effects of curcumin on WEHI-3 in BALB/c mice and the results indicated that curcumin reduces the percentage of Mac-3 marker, which is the precursor of macrophage. Curcumin induced significant effects on the population of B cells from murine leukemia in vivo. We also investigated the weights of spleen and liver from murine leukemia and the results showed that curcumin reduced the weight of the liver and spleen. From the pathological examinations, the effects of curcumin on the liver and spleen from mice after being injected with WEHI-3 cells were apparent. Both organs were enlarged. In conclusion, curcumin affect WEHI-3 cells in vivo.</description>
    <dc:title>Curcumin inhibits WEHI-3 leukemia cells in BALB/c mice in vivo.</dc:title>

    <dc:creator>CC Su</dc:creator>
    <dc:creator>JS Yang</dc:creator>
    <dc:creator>SY Lin</dc:creator>
    <dc:creator>HF Lu</dc:creator>
    <dc:creator>SS Lin</dc:creator>
    <dc:creator>YH Chang</dc:creator>
    <dc:creator>WW Huang</dc:creator>
    <dc:creator>YC Li</dc:creator>
    <dc:creator>SJ Chang</dc:creator>
    <dc:creator>JG Chung</dc:creator>
    <dc:source>In vivo (Athens, Greece), Vol. 22, No. 1. (b 2008), pp. 63-68.</dc:source>
    <dc:date>2008-04-29T16:18:45-00:00</dc:date>
    <prism:publicationYear>2008</prism:publicationYear>
    <prism:publicationName>In vivo (Athens, Greece)</prism:publicationName>
    <prism:issn>0258-851X</prism:issn>
    <prism:volume>22</prism:volume>
    <prism:number>1</prism:number>
    <prism:startingPage>63</prism:startingPage>
    <prism:endingPage>68</prism:endingPage>
    <prism:category>cancer</prism:category>
    <prism:category>curcumin</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/carmenv/article/2734788">
    <title>Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells.</title>
    <link>http://www.citeulike.org/user/carmenv/article/2734788</link>
    <description>&lt;i&gt;International journal of oncology, Vol. 32, No. 5. (May 2008), pp. 1119-1123.&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;We have initiated studies to enhance targeted delivery of an anticancer agent, curcumin, for prostate cancer treatment by incorporating this agent into the liposomes (nanodelivery vehicles primarily composed of phospholipids) coated with prostate membrane specific antigen specific antibodies. We prepared curcumin-loaded liposomes of various lipid compositions by sonication at an average size of 100-150 nm. Un-entrapped curcumin was removed by size exclusion chromatography. Data show that curcumin preferentially partitioned into liposomes prepared from dimyristoyl phosphatidyl choline (DMPC) and cholesterol among the various compositions tested. The anti-proliferative activity of liposomal curcumin was studied using two human prostate cancer cell lines (LNCaP and C4-2B) by a tetrazolium dye-based (MTT) assay. Treatment of cells with liposomal curcumin (5-10 microM) for 24-48 h at 37 degrees C resulted in at least 70-80% inhibition of cellular proliferation without affecting their viability. On the other hand, free curcumin exhibited similar inhibition only at 10-fold higher doses (&#62;50 microM). We also observed that LNCaP cells were relatively more sensitive to liposomal curcumin mediated block of cellular proliferation than C4-2B cells. We are currently developing liposome formulations with targeting ability to further improve the efficacy of curcumin in vivo.</description>
    <dc:title>Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells.</dc:title>

    <dc:creator>RL Thangapazham</dc:creator>
    <dc:creator>A Puri</dc:creator>
    <dc:creator>S Tele</dc:creator>
    <dc:creator>R Blumenthal</dc:creator>
    <dc:creator>RK Maheshwari</dc:creator>
    <dc:source>International journal of oncology, Vol. 32, No. 5. (May 2008), pp. 1119-1123.</dc:source>
    <dc:date>2008-04-29T16:07:45-00:00</dc:date>
    <prism:publicationYear>2008</prism:publicationYear>
    <prism:publicationName>International journal of oncology</prism:publicationName>
    <prism:issn>1019-6439</prism:issn>
    <prism:volume>32</prism:volume>
    <prism:number>5</prism:number>
    <prism:startingPage>1119</prism:startingPage>
    <prism:endingPage>1123</prism:endingPage>
    <prism:category>cancer</prism:category>
    <prism:category>curcumin</prism:category>
</item>



<item rdf:about="http://www.citeulike.org/user/carmenv/article/2734779">
    <title>Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways.</title>
    <link>http://www.citeulike.org/user/carmenv/article/2734779</link>
    <description>&lt;i&gt;International journal of pharmaceutics (18 March 2008)&lt;/i&gt;&lt;br /&gt;&lt;br /&gt;Curcumin is a phenolic compound isolated from rhizomes of C. longa, C. aromatica and other Curcumas except C. zedoaria. Recently, both curcumin and Curcumas have become prevalent as supplement. P-gp has been reported as an important determinant for drug absorption in small intestine. In this study, Caco-2 cell monolayers were treated with methanol extracts of Curcumas (0.1mg/ml) or curcumin (30muM) for 72h to investigate the relationship between the potential affects of Curcumas and curcumin on P-gp. [(3)H]-digoxin and rhodamine 123 were used to evaluate P-gp activity. All Curcumas significantly increased the activity of P-gp by up-regulating the expressions of P-gp protein and MDR1 mRNA levels. Interestingly, contrary to Curcumas, curcumin treatment inhibited the activity of P-gp with a decrease in P-gp protein and MDR1 mRNA expression levels. Curcumas might alter the pharmacokinetics of co-administrated drugs by up-regulating the function and expression levels of intestinal P-gp. However, curcumin has no relationship with the inductive effect of Curcumas since curcumin showed an opposite effects. Caution should be exercised when Curcumas or curcumin are to be consumed with drugs that are P-gp substrates because Curcumas and curcumin might regulate the function of P-gp in completely opposite ways.</description>
    <dc:title>Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways.</dc:title>

    <dc:creator>Xiao-Long Hou</dc:creator>
    <dc:creator>Kyoko Takahashi</dc:creator>
    <dc:creator>Ken Tanaka</dc:creator>
    <dc:creator>Katsuhiko Tougou</dc:creator>
    <dc:creator>Feng Qiu</dc:creator>
    <dc:creator>Katsuko Komatsu</dc:creator>
    <dc:creator>Koichi Takahashi</dc:creator>
    <dc:creator>Junichi Azuma</dc:creator>
    <dc:identifier>doi:10.1016/j.ijpharm.2008.03.010</dc:identifier>
    <dc:source>International journal of pharmaceutics (18 March 2008)</dc:source>
    <dc:date>2008-04-29T16:04:01-00:00</dc:date>
    <prism:publicationYear>2008</prism:publicationYear>
    <prism:publicationName>International journal of pharmaceutics</prism:publicationName>
    <prism:issn>0378-5173</prism:issn>
    <prism:category>and</prism:category>
    <prism:category>cancer</prism:category>
    <prism:category>curcumin</prism:category>
</item>



</rdf:RDF>

